Rocket Lab’s Market Paradox: Record Contracts Can’t Lift a Stock Caught in a Sector Storm
Published on 07/26/2026 at 13:52 | Redaktion boerse-global.de
Rocket Lab is firing on all cylinders operationally, yet its share price is in freefall. The space company secured a $90 million contract from the US Space Force for geostationary satellites, added to a $266 million suborbital launch deal, and closed an $8 billion acquisition of Iridium Communications — all while the stock slumped 8.29% in a single session to €56.40 on Friday. The disconnect between corporate execution and market reception has rarely been starker.
The latest Space Force win builds on the company’s demonstrated speed under the Tactically Responsive Launch (TacRS) program. Rocket Lab’s Electron rocket launched the Victus Haze mission within 16 hours and 42 minutes of receiving the order, well inside the 24-hour requirement. The satellite was operational 37 hours and 36 minutes after liftoff, completing a rendezvous maneuver with True Anomaly’s Jackal-004 spacecraft. That performance improved on the 2023 predecessor mission, Victus Nox, which took 27 hours. The company now holds a record backlog of $2.2 billion, including a role in the National Security Space Launch program with a potential contract ceiling of $17 billion.
None of that has insulated the stock from a brutal sector-wide rout. The catalyst appears to be a reported cut in SpaceX’s IPO valuation target from $2 trillion to roughly $1.8 trillion, which triggered selling across the space ecosystem. AST SpaceMobile, Redwire, and Intuitive Machines all fell in after-hours trading alongside Rocket Lab. A similar wave hit on June 1, when Rocket Lab lost about 15% following a Blue Origin New Glenn static-test explosion and an earlier SpaceX downgrade. Investors are treating the entire sector as a single risk factor, punishing even companies with full order books.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The technical picture reinforces the bearish mood. Rocket Lab’s 14-day relative strength index has dropped to 30.8, flirting with oversold territory. The stock now trades 16.27% below its 200-day moving average of €67.36, a level that often signals a breakdown in long-term support. With annualized volatility above 88%, oversold doesn’t mean a bottom is in. The share price sits 57.85% below its 52-week high of €133.80, reached on May 27.
Institutional investors are sending mixed signals. Themes Management Co boosted its Rocket Lab stake by 94.8% in the first quarter to roughly 24,000 shares. First Trust Advisors cut its position by 20.1% but still holds a $75.78 million stake. Caxton Associates trimmed its smaller holding by 28.7%. Meanwhile, company insiders have sold $362.8 million worth of shares over the past three months. Notable transactions include Frank Klein’s sale of about 36,000 shares at $147.42 in late May and SVP Arjun Kampani’s disposal of 88,000 shares at $107.98 in mid-June — both executed at prices far above current levels.
The valuation debate remains unresolved. A discounted cash flow model from Simply Wall St pegs fair value at $83.68, suggesting the stock is undervalued. Yet Rocket Lab’s price-to-book ratio of 16.9 dwarfs the industry average of 3.7, and the company meets only three of six common valuation criteria. Analysts maintain a moderate buy consensus with a price target of $110.18, implying roughly 78% upside from current levels. The market capitalization of €44.36 billion already prices Rocket Lab as a full-spectrum space applications provider, not a pure launch company — a premium that leaves the stock vulnerable to sentiment shifts and doubts about the Neutron rocket’s financing, with its debut slated for late 2026.
The next major catalyst arrives on August 10, when Rocket Lab reports second-quarter results after the US market close. The first quarter showed revenue growth of 63.4% to $200.35 million, and investors will watch closely whether that pace can hold. For now, the company has delivered operationally — the Iridium deal, the Space Force contracts, the record backlog — but the market isn’t rewarding those achievements. The question isn’t whether Rocket Lab can execute; it’s whether the broader sector rotation will allow the stock to reflect that execution before the next earnings print. Over the past 12 months, the shares still show a gain of 37.56%, but the 25% monthly decline suggests patience is wearing thin.
Ad
Rocket Lab Stock: New Analysis - 26 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
